BRAF and non-small cell lung carcinoma: Vemurafenib, another BRAF inhibitor, was administered in 115 pretreated NSCLC patients (100 with BRAFV600 mutations and 15 with BRAF.nonV600 mutations) as part of the AcSè program conducted by the French National Cancer Institute (25).